Can Health Technology Assessment Control Spending and Reward Innovation?
The pressure to curb U.S. healthcare spending keeps growing, but fear about what that might entail – including rationing of treatments or price controls that could stifle innovation – stops action. Unlike other advanced nations, the United States does not have a coordinated process to evaluate the effectiveness and value of new devices, medicines, or procedures. Could an Institute of Health Technology Assessment facilitate more rational decisions on healthcare that reward both innovation and quality across the entire spectrum of care?
Join the Aspen Institute and the USC Schaeffer Center for a discussion with Gail Wilensky, Peter Neumann, and Darius Lakdawalla – lead authors of a recently released white paper that paves the way for a new approach to health technology assessment in the U.S. Joining the conversation will be Lee A. Fleisher, chief medical officer and director of the Center for Clinical Standards and Quality at CMS and Adrian Towse, director emeritus and senior research fellow at the UK’s Office of Health Economics. The conversations will be moderated by STAT Washington Correspondent Rachel Cohrs.